# Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

Study · id `cardio:ct-nct04020263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04020263](<https://clinicaltrials.gov/study/NCT04020263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04020263

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 610 participants.

## Technical summary

Registry record NCT04020263. Randomized; triple masking; primary purpose treatment. Start 2023-07-03 (actual); primary completion 2027-02-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 610 participants (planned count; ClinicalTrials.gov record NCT04020263, source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)
- Started: 2023-07-03 (actual) (ClinicalTrials.gov record NCT04020263, source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)
- Primary completion: 2027-02-03 (anticipated) (ClinicalTrials.gov record NCT04020263, source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)
- Completion: 2028-01-03 (anticipated) (ClinicalTrials.gov record NCT04020263, source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04020263, source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04020263-2025-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
- Acronym: LevoHeartShock
- Condition: Cardiogenic Shock
- Intervention (Drug): Levosimendan 2.5 MG/ML Injectable Solution
- Intervention (Drug): Placebo
- Lead sponsor: Pr Bruno LEVY
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 616324abb24b2538721236185ca1fa691f1467a16096c0b8c3070056d24a9c5b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
